TICKERNERD
Menu
PRQRPRQRHealthcare · Biotechnology

PRQR Stock Forecast: ProQR Therapeutics NV Price Predictions for 2026-2027

Last close, 24 Aug 2026
$2.43
+3.85% on the day

The 9 Wall Street analysts covering ProQR Therapeutics NV hold a median 12-month price target of $8 — +229.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$330.2M
Ticker Nerd rank
47 / 100
Median analyst target
$8.00
Analysts covering
9
Revenue$2.0M−55.0% y/y
Operating income−$13.6M
Net income−$13.4M
Free cash flow−$11.3M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+25.9%
1M
+41.3%
YTD
+20.3%
1Y
+7.5%
From 52W high
−20.3%
From 52W low
+77.4%
$1.37
$3.05
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRQR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ProQR Therapeutics NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
69
Growth
68
Size
61
Issuance
50
Value
49
Momentum
44
Quality
39
Accruals
31
Volatility
24

Revisions (69): Analysts have, on balance, been raising their forecasts.

Volatility (24): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PRQR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRQR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26PRQRHigh $12.00Median $8.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $3.00Median $8.00High $12.00

The green dot is the last close — the median target sits +229.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
20 Aug 2026B of A SecuritiesInitiatesBuy$8.00
29 June 2026Evercore ISI GroupMaintainsOutperform$5.00 → $6.00
29 June 2026Evercore ISI GroupMaintainsOutperform—
26 June 2026Chardan CapitalMaintainsBuy$4.00 → $3.00
26 June 2026Chardan CapitalMaintainsBuy—
26 June 2026Jones TradingMaintainsBuy$11 → $10
26 June 2026Jones TradingMaintainsBuy—
9 Apr 2026Chardan CapitalMaintainsBuy—
4 Nov 2025Chardan CapitalMaintainsBuy—
8 Aug 2025Chardan CapitalMaintainsBuy—
27 June 2025Cantor FitzgeraldReiteratesOverweight—
27 June 2025JMP SecuritiesReiteratesMarket Outperform—
13 May 2025OppenheimerMaintainsOutperform—
29 Apr 2025Evercore ISI GroupInitiatesOutperform—
14 Mar 2025Chardan CapitalMaintainsBuy—
14 Mar 2025HC Wainwright & Co.MaintainsBuy—
12 Feb 2025Jones TradingInitiatesBuy—
12 Dec 2024Chardan CapitalMaintainsBuy—
12 Dec 2024HC Wainwright & Co.ReiteratesBuy—
12 Dec 2024JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRQR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PRQR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, ProQR Therapeutics NV returned +7.5% against +19.6% for the S&P 500, dividends included.

PRQR vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26PRQRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PRQR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

ProQR Therapeutics NV (PRQR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.8×

Cheaper than 90% of US stocks

Price / sales
17.9×

Cheaper than 10% of US stocks

Price / book
2.8×

Cheaper than 37% of US stocks

EV / EBITDA
−3.7×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
120.4%

Higher than 94% of US stocks

Earnings growth (YoY)
−55.0%

Higher than 9% of US stocks

Gross margin
—
Operating margin
−100.7%

Higher than 13% of US stocks

Net margin
−228.2%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−57.4%

Higher than 20% of US stocks

Return on assets
−19.8%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ProQR Therapeutics NV (PRQR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ProQR Therapeutics NV has a market value of $330.2M and an enterprise value of $181.5M.

  • Revenue in the twelve months to 31 Mar 2026: $13.4M. The latest quarter grew 120.4% year on year.

  • Net income over the same four quarters: −$45.5M, a −339.0% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$49.1M, after $960K of capital spending.

  • Shares outstanding: 105.4M.

  • Trailing P/E: −5.8×; forward P/E: −4.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • ProQR Therapeutics NV employs 186 people — $72K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

PRQR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PRQRProQR Therapeutics NV$330.2M
47
VNDAVanda Pharmaceuticals, Inc.$312.1M
44
IFRXInflaRx NV$309.3M
9
OBIOOrchestra Biomed Holdings, Inc.$313.7M
36
AVXLAnavex Life Sciences Corp.$300.3M
21
NMRANeumora Therapeutics, Inc.$296.7M
36
RNACCartesian Therapeutics, Inc.$294.2M
25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ProQR Therapeutics NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRQR news & analysis

ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts

Seeking Alpha · 21 Aug 2026positive

A Seeking Alpha article covers ProQR Therapeutics N.V., reporting that its Axiomer RNA editing platform achieved initial human proof-of-concept. The company's AX-0810 produced an 8-fold serum bile acid increase in phase 1, exceeding its 2-fold target and supporting potential disease-modifying effects in biliary atresia. Upcoming catalysts cited include full phase 1 data for AX-0810 by end-2026, pediatric biliary atresia data from China in H1 2027, and phase 1 data for next-generation AX-0811 by end-2026.

Why it matters — PRQR watchers would follow this because positive early phase 1 results for Axiomer and the listed timelines offer a near-term view of the company's lead program and platform progress.

ProQR Announces Second Quarter 2026 Operating and Financial Results

GlobeNewsWire · 13 Aug 2026neutral

ProQR Therapeutics reported its operating and financial results for the second quarter ended June 30, 2026, and provided a business update. The announcement covers the clinical-stage company's progress with its Axiomer RNA editing platform.

Why it matters — A PRQR watcher would care because the quarterly results and business update offer insight into the company's financial position and progress with its Axiomer RNA editing programs.

FAQ

Frequently asked questions about PRQR stock

What is the PRQR stock price forecast for 2026-2027?

The 9 Wall Street analysts covering ProQR Therapeutics NV have a median 12-month price target of $8, with estimates ranging from $3 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PRQR stock a buy right now?

Of the 9 analysts covering ProQR Therapeutics NV, 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ProQR Therapeutics NV 47 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRQR?

As at 22 Aug 2026, ProQR Therapeutics NV ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (69 of 100).

Will PRQR stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +229.2% from the last close, and Ticker Nerd's factor model ranks ProQR Therapeutics NV 47 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PRQR stock forecast for 2030?

No analyst covering ProQR Therapeutics NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRQR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $12 over the next 12 months.

How has PRQR stock performed over the past year?

ProQR Therapeutics NV returned +7.5% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ProQR Therapeutics NV do?

ProQR Therapeutics N.V. is a biotechnology company specializing in the development of transformative RNA-based therapies for genetic disorders.

What is the latest news on PRQR?

The most recent item we track (Seeking Alpha, 21 Aug 2026): "ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts". A Seeking Alpha article covers ProQR Therapeutics N.V., reporting that its Axiomer RNA editing platform achieved initial human proof-of-concept. The company's AX-0810 produced an 8-fold serum bile acid increase in phase 1, exceeding its 2-fold target and supporting potential disease-modifying effects in biliary atresia. Upcoming catalysts cited include full phase 1 data for AX-0810 by end-2026, pediatric biliary atresia data from China in H1 2027, and phase 1 data for next-generation AX-0811 by end-2026.

Company

About ProQR Therapeutics NV.

ProQR Therapeutics N.V. is a biotechnology company specializing in the development of transformative RNA-based therapies for genetic disorders. Founded in 2012 and based in the Netherlands, the company focuses on targeting genetic eye diseases like Leber congenital amaurosis 10 (LCA10) and Usher syndrome, along with other rare genetic disorders. ProQR's innovative approach utilizes RNA-editing technologies to address underlying genetic mutations, offering potential treatment breakthroughs where no effective alternatives currently exist. Renowned for its commitment to genetic research and innovation, ProQR plays a significant role in the life sciences sector, particularly in the field of genetic condition therapeutics. Its work on exon-skipping and RNA-editing not only exemplifies cutting-edge science but also highlights the burgeoning role of RNA therapy in modern medicine. The company's pipeline of therapies underlines its dedication to creating meaningful, long-term impacts for patients with unmet medical needs, thereby influencing both the biotechnology industry and the broader healthcare landscape. As such, ProQR Therapeutics positions itself at the intersection of technology and healthcare, aiming to unlock new possibilities in genetic disease treatment.

CEO Mr. Daniel Anton de Boer · 186 employees · Netherlands · https://www.proqr.com